These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36898078)

  • 1. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
    Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
    J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
    ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
    Kang EJ; Ahn MJ; Ock CY; Lee KW; Kwon JH; Yang Y; Choi YH; Kim MK; Ji JH; Yun T; Nam BH; Kim SB; Keam B
    Clin Cancer Res; 2021 Oct; 27(19):5272-5279. PubMed ID: 34315722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
    Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
    Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
    N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
    Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
    Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
    Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
    Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
    Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
    ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
    Larkin J; Oya M; Martignoni M; Thistlethwaite F; Nathan P; Ornstein MC; Powles T; Beckermann KE; Balar AV; McDermott D; Gupta S; Philips GK; Gordon MS; Uemura H; Tomita Y; Wang J; Michelon E; di Pietro A; Choueiri TK
    Oncologist; 2023 Apr; 28(4):333-340. PubMed ID: 36576173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).
    Bex A; van Thienen JV; Schrier M; Graafland N; Kuusk T; Hendricksen K; Lagerveld B; Zondervan P; van Moorselaar JA; Blank C; Wilgenhof S; Haanen J
    Future Oncol; 2019 Jul; 15(19):2203-2209. PubMed ID: 31023100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
    Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
    Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
    Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
    Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
    Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
    Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
    Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
    ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
    Awada G; Ben Salama L; De Cremer J; Schwarze JK; Fischbuch L; Seynaeve L; Du Four S; Vanbinst AM; Michotte A; Everaert H; Rogiers A; Theuns P; Duerinck J; Neyns B
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
    Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse J
    Liver Cancer; 2021 Jun; 10(3):249-259. PubMed ID: 34239811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.